| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neovascularization, Pathologic | 42 | 2024 | 2631 | 3.310 |
Why?
|
| Matrix Metalloproteinase 9 | 23 | 2018 | 633 | 3.000 |
Why?
|
| Matrix Metalloproteinase 2 | 30 | 2022 | 461 | 2.940 |
Why?
|
| Matrix Metalloproteinases | 20 | 2019 | 393 | 2.730 |
Why?
|
| Lipocalins | 11 | 2016 | 161 | 2.230 |
Why?
|
| Acute-Phase Proteins | 10 | 2016 | 252 | 2.110 |
Why?
|
| Metalloendopeptidases | 22 | 2011 | 386 | 1.850 |
Why?
|
| Blood-Brain Barrier | 4 | 2025 | 1034 | 1.550 |
Why?
|
| Neovascularization, Physiologic | 14 | 2014 | 1369 | 1.430 |
Why?
|
| Breast Neoplasms | 24 | 2025 | 21206 | 1.350 |
Why?
|
| Vascular Endothelial Growth Factor A | 19 | 2022 | 3514 | 1.260 |
Why?
|
| Cell Movement | 16 | 2024 | 5210 | 1.250 |
Why?
|
| Fibroblast Growth Factor 2 | 9 | 2022 | 590 | 1.210 |
Why?
|
| Intercellular Adhesion Molecule-1 | 7 | 2023 | 1134 | 1.200 |
Why?
|
| Mammary Neoplasms, Experimental | 3 | 2022 | 506 | 1.170 |
Why?
|
| Extracellular Matrix | 14 | 2020 | 1738 | 1.140 |
Why?
|
| STAT3 Transcription Factor | 2 | 2024 | 874 | 1.100 |
Why?
|
| Cell Line, Tumor | 30 | 2025 | 17140 | 1.050 |
Why?
|
| Endothelial Cells | 14 | 2025 | 3589 | 1.040 |
Why?
|
| Angiogenesis Inhibitors | 14 | 2016 | 2056 | 1.040 |
Why?
|
| Liposomes | 8 | 2019 | 790 | 1.040 |
Why?
|
| ADAM Proteins | 6 | 2015 | 242 | 1.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 9 | 2022 | 71 | 1.000 |
Why?
|
| Adipocytes | 2 | 2024 | 1197 | 0.970 |
Why?
|
| Kruppel-Like Transcription Factors | 3 | 2014 | 507 | 0.960 |
Why?
|
| Proto-Oncogene Proteins | 11 | 2016 | 4528 | 0.910 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 17 | 2009 | 97 | 0.900 |
Why?
|
| Transcytosis | 2 | 2025 | 48 | 0.900 |
Why?
|
| Pelvic Pain | 4 | 2021 | 300 | 0.880 |
Why?
|
| Immunoconjugates | 2 | 2023 | 975 | 0.880 |
Why?
|
| Cell Proliferation | 21 | 2024 | 10474 | 0.820 |
Why?
|
| Drug Delivery Systems | 5 | 2020 | 2232 | 0.780 |
Why?
|
| Urologic Diseases | 3 | 2020 | 246 | 0.780 |
Why?
|
| Endocytosis | 3 | 2020 | 956 | 0.710 |
Why?
|
| Cytoskeleton | 1 | 2025 | 1179 | 0.660 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2020 | 188 | 0.660 |
Why?
|
| Integrin alpha2 | 1 | 2019 | 39 | 0.650 |
Why?
|
| Drug Carriers | 2 | 2019 | 709 | 0.630 |
Why?
|
| Cattle | 18 | 2014 | 3819 | 0.620 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 7 | 2010 | 149 | 0.610 |
Why?
|
| Flow Cytometry | 4 | 2019 | 5902 | 0.600 |
Why?
|
| Progeria | 2 | 2018 | 188 | 0.590 |
Why?
|
| Menopause | 2 | 2024 | 1656 | 0.590 |
Why?
|
| Blood Vessels | 4 | 2012 | 1110 | 0.590 |
Why?
|
| Neoplasms | 15 | 2020 | 22371 | 0.560 |
Why?
|
| Nanoparticles | 3 | 2019 | 1985 | 0.560 |
Why?
|
| Elastic Modulus | 1 | 2018 | 211 | 0.550 |
Why?
|
| Time-Lapse Imaging | 1 | 2018 | 194 | 0.550 |
Why?
|
| Holography | 1 | 2017 | 80 | 0.530 |
Why?
|
| Up-Regulation | 9 | 2017 | 4146 | 0.530 |
Why?
|
| Sports | 1 | 2021 | 703 | 0.490 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2019 | 757 | 0.470 |
Why?
|
| Corpus Luteum | 5 | 2011 | 81 | 0.470 |
Why?
|
| Neoplasm Metastasis | 9 | 2020 | 4912 | 0.470 |
Why?
|
| Estrous Cycle | 4 | 2011 | 65 | 0.450 |
Why?
|
| Ovarian Neoplasms | 4 | 2019 | 4916 | 0.450 |
Why?
|
| Plasminogen | 5 | 2003 | 144 | 0.440 |
Why?
|
| Membrane Proteins | 6 | 2015 | 7876 | 0.420 |
Why?
|
| Cartilage | 5 | 1999 | 811 | 0.420 |
Why?
|
| Chondrosarcoma | 4 | 2001 | 306 | 0.420 |
Why?
|
| Animals | 91 | 2022 | 169246 | 0.410 |
Why?
|
| Blood Proteins | 1 | 2018 | 1191 | 0.400 |
Why?
|
| Astrocytes | 1 | 2020 | 1350 | 0.400 |
Why?
|
| Endothelium, Vascular | 18 | 2007 | 4427 | 0.400 |
Why?
|
| Cysteine-Rich Protein 61 | 1 | 2011 | 39 | 0.370 |
Why?
|
| Lymphangioleiomyomatosis | 3 | 2010 | 207 | 0.370 |
Why?
|
| Athletic Injuries | 1 | 2021 | 1245 | 0.370 |
Why?
|
| Obesity | 3 | 2024 | 13090 | 0.370 |
Why?
|
| Prostatic Hyperplasia | 1 | 2015 | 516 | 0.370 |
Why?
|
| Osteosarcoma | 1 | 2017 | 911 | 0.360 |
Why?
|
| Dinoprost | 1 | 2011 | 139 | 0.360 |
Why?
|
| Mice, Nude | 8 | 2020 | 3623 | 0.360 |
Why?
|
| Polymers | 7 | 2007 | 1630 | 0.360 |
Why?
|
| Humans | 111 | 2025 | 768166 | 0.360 |
Why?
|
| rab GTP-Binding Proteins | 2 | 2025 | 247 | 0.360 |
Why?
|
| Glioblastoma | 3 | 2019 | 3464 | 0.350 |
Why?
|
| Endothelium | 4 | 2019 | 768 | 0.350 |
Why?
|
| Brain Concussion | 1 | 2021 | 1435 | 0.340 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2011 | 1099 | 0.330 |
Why?
|
| Peptide Hydrolases | 3 | 2006 | 610 | 0.330 |
Why?
|
| Carcinoma, Lewis Lung | 4 | 2003 | 107 | 0.330 |
Why?
|
| Uterine Diseases | 1 | 2010 | 108 | 0.320 |
Why?
|
| Endothelial Growth Factors | 5 | 2003 | 671 | 0.320 |
Why?
|
| Piperidines | 1 | 2018 | 1667 | 0.320 |
Why?
|
| RNA, Small Interfering | 6 | 2019 | 3428 | 0.320 |
Why?
|
| CA-125 Antigen | 1 | 2011 | 281 | 0.320 |
Why?
|
| Female | 63 | 2025 | 397192 | 0.310 |
Why?
|
| Adenocarcinoma | 3 | 2015 | 6395 | 0.310 |
Why?
|
| Nanomedicine | 3 | 2020 | 292 | 0.310 |
Why?
|
| Estrogen Receptor alpha | 2 | 2009 | 581 | 0.300 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2010 | 384 | 0.300 |
Why?
|
| Metalloproteases | 1 | 2008 | 60 | 0.300 |
Why?
|
| Neoplasm Proteins | 3 | 2011 | 3603 | 0.300 |
Why?
|
| Stomach Neoplasms | 2 | 2017 | 1481 | 0.300 |
Why?
|
| Polyesters | 3 | 2005 | 377 | 0.300 |
Why?
|
| Proteomics | 5 | 2025 | 3912 | 0.300 |
Why?
|
| Cells, Cultured | 22 | 2017 | 19015 | 0.290 |
Why?
|
| Hypercholesterolemia | 1 | 2014 | 1145 | 0.280 |
Why?
|
| Glycoproteins | 8 | 2011 | 2202 | 0.280 |
Why?
|
| Liver Regeneration | 2 | 2008 | 214 | 0.270 |
Why?
|
| Pharynx | 2 | 2007 | 436 | 0.270 |
Why?
|
| Matrix Metalloproteinase 1 | 6 | 2007 | 147 | 0.270 |
Why?
|
| Gene Expression Regulation, Enzymologic | 4 | 2007 | 1169 | 0.270 |
Why?
|
| Amino Acid Sequence | 16 | 2014 | 13421 | 0.260 |
Why?
|
| Protease Inhibitors | 6 | 2010 | 751 | 0.260 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2019 | 5341 | 0.260 |
Why?
|
| Mouth | 2 | 2007 | 383 | 0.260 |
Why?
|
| Mice | 37 | 2022 | 82029 | 0.260 |
Why?
|
| Oligopeptides | 1 | 2011 | 1194 | 0.260 |
Why?
|
| Antineoplastic Agents | 8 | 2020 | 13676 | 0.260 |
Why?
|
| Pyridines | 1 | 2018 | 2894 | 0.260 |
Why?
|
| Urinary Tract | 2 | 2017 | 305 | 0.260 |
Why?
|
| Tissue Engineering | 6 | 2010 | 1893 | 0.260 |
Why?
|
| Molecular Sequence Data | 16 | 2014 | 17622 | 0.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2019 | 8647 | 0.260 |
Why?
|
| Cell Division | 13 | 2005 | 4473 | 0.250 |
Why?
|
| Vascular Endothelial Growth Factors | 5 | 2022 | 748 | 0.250 |
Why?
|
| MicroRNAs | 2 | 2020 | 3803 | 0.250 |
Why?
|
| Ureteral Obstruction | 2 | 2022 | 293 | 0.250 |
Why?
|
| Polydioxanone | 1 | 2005 | 8 | 0.250 |
Why?
|
| Doxorubicin | 3 | 2019 | 2234 | 0.250 |
Why?
|
| Sturge-Weber Syndrome | 2 | 2018 | 89 | 0.240 |
Why?
|
| Neoplasm Transplantation | 4 | 2017 | 2014 | 0.240 |
Why?
|
| Bioprosthesis | 2 | 2010 | 593 | 0.240 |
Why?
|
| Proteome | 3 | 2025 | 1890 | 0.240 |
Why?
|
| Blotting, Western | 11 | 2014 | 5027 | 0.240 |
Why?
|
| Absorbable Implants | 5 | 2006 | 337 | 0.230 |
Why?
|
| Neoplasm Invasiveness | 6 | 2024 | 3620 | 0.230 |
Why?
|
| Craniopharyngioma | 1 | 2007 | 279 | 0.230 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2011 | 934 | 0.230 |
Why?
|
| Respiratory System | 1 | 2007 | 564 | 0.230 |
Why?
|
| Cloning, Molecular | 8 | 2005 | 4168 | 0.230 |
Why?
|
| Doxycycline | 1 | 2006 | 349 | 0.230 |
Why?
|
| Estrogens | 1 | 2011 | 1536 | 0.230 |
Why?
|
| Mouth Mucosa | 1 | 2007 | 435 | 0.230 |
Why?
|
| Colonic Polyps | 1 | 2009 | 557 | 0.220 |
Why?
|
| Microscopy, Atomic Force | 2 | 2018 | 250 | 0.220 |
Why?
|
| Molecular Weight | 6 | 2008 | 2173 | 0.220 |
Why?
|
| Vascular Neoplasms | 1 | 2005 | 167 | 0.220 |
Why?
|
| Fluorescent Dyes | 1 | 2011 | 1930 | 0.220 |
Why?
|
| DNA, Complementary | 6 | 2007 | 1989 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2024 | 2457 | 0.210 |
Why?
|
| Gelatin | 6 | 2007 | 231 | 0.210 |
Why?
|
| Culture Media, Conditioned | 4 | 2020 | 521 | 0.210 |
Why?
|
| Prostatic Neoplasms | 5 | 2015 | 11101 | 0.210 |
Why?
|
| Down-Regulation | 4 | 2019 | 2937 | 0.210 |
Why?
|
| RNA, Messenger | 14 | 2014 | 12800 | 0.210 |
Why?
|
| Cell Culture Techniques | 3 | 2007 | 1667 | 0.210 |
Why?
|
| Gene Knockdown Techniques | 2 | 2019 | 1606 | 0.210 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2017 | 3814 | 0.200 |
Why?
|
| Peptide Fragments | 6 | 2003 | 5151 | 0.200 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2022 | 60 | 0.200 |
Why?
|
| Phosphoprotein Phosphatases | 2 | 2001 | 327 | 0.200 |
Why?
|
| Proteins | 7 | 2009 | 6009 | 0.200 |
Why?
|
| Case-Control Studies | 8 | 2018 | 22291 | 0.200 |
Why?
|
| Signal Transduction | 11 | 2024 | 23645 | 0.200 |
Why?
|
| Hepatectomy | 2 | 2008 | 588 | 0.200 |
Why?
|
| ROC Curve | 3 | 2015 | 3628 | 0.190 |
Why?
|
| Repressor Proteins | 1 | 2012 | 2982 | 0.190 |
Why?
|
| Endometriosis | 1 | 2010 | 873 | 0.190 |
Why?
|
| Syndrome | 4 | 2021 | 3272 | 0.190 |
Why?
|
| Mice, Obese | 1 | 2022 | 417 | 0.190 |
Why?
|
| Gastrointestinal Tract | 1 | 2007 | 840 | 0.190 |
Why?
|
| Molecular Targeted Therapy | 5 | 2019 | 2830 | 0.190 |
Why?
|
| Collagenases | 4 | 1998 | 221 | 0.190 |
Why?
|
| Hydroxamic Acids | 4 | 2010 | 483 | 0.190 |
Why?
|
| Antibodies | 2 | 2019 | 2421 | 0.180 |
Why?
|
| Colon | 1 | 2009 | 1801 | 0.180 |
Why?
|
| Growth Substances | 2 | 1995 | 759 | 0.180 |
Why?
|
| Hydronephrosis | 1 | 2022 | 274 | 0.180 |
Why?
|
| Lymphokines | 4 | 2003 | 924 | 0.180 |
Why?
|
| Cytoplasm | 2 | 2025 | 1505 | 0.180 |
Why?
|
| Esophagus | 1 | 2007 | 1042 | 0.180 |
Why?
|
| Brain Neoplasms | 4 | 2025 | 9118 | 0.180 |
Why?
|
| Gastrointestinal Diseases | 1 | 2009 | 1206 | 0.180 |
Why?
|
| Protein Array Analysis | 2 | 2015 | 399 | 0.170 |
Why?
|
| Allantois | 4 | 2003 | 32 | 0.170 |
Why?
|
| Base Sequence | 8 | 2012 | 12421 | 0.170 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2004 | 832 | 0.170 |
Why?
|
| SNARE Proteins | 1 | 2019 | 80 | 0.160 |
Why?
|
| Wound Healing | 4 | 2014 | 2809 | 0.160 |
Why?
|
| Rats | 10 | 2007 | 23760 | 0.160 |
Why?
|
| Caveolins | 1 | 2019 | 102 | 0.160 |
Why?
|
| Gene Expression Regulation | 5 | 2012 | 11928 | 0.160 |
Why?
|
| Port-Wine Stain | 1 | 2018 | 33 | 0.160 |
Why?
|
| Tumor Microenvironment | 2 | 2024 | 3948 | 0.160 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2023 | 3611 | 0.160 |
Why?
|
| Interleukin-6 | 3 | 2024 | 3228 | 0.160 |
Why?
|
| Burkitt Lymphoma | 1 | 2001 | 338 | 0.150 |
Why?
|
| Pituitary Neoplasms | 1 | 2007 | 1322 | 0.150 |
Why?
|
| Rats, Sprague-Dawley | 7 | 2007 | 8128 | 0.150 |
Why?
|
| Vascular Diseases | 2 | 2005 | 1162 | 0.150 |
Why?
|
| Pneumonia, Bacterial | 1 | 2021 | 320 | 0.150 |
Why?
|
| Filipin | 1 | 2018 | 14 | 0.150 |
Why?
|
| Receptors, CXCR4 | 2 | 2014 | 729 | 0.150 |
Why?
|
| Lipids | 2 | 2019 | 3343 | 0.150 |
Why?
|
| Basement Membrane | 1 | 1999 | 348 | 0.150 |
Why?
|
| Prognosis | 9 | 2021 | 30010 | 0.150 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2012 | 4580 | 0.150 |
Why?
|
| Chlorpromazine | 1 | 2018 | 111 | 0.150 |
Why?
|
| Arachidonic Acid | 1 | 2019 | 429 | 0.150 |
Why?
|
| Angiostatins | 6 | 2012 | 64 | 0.150 |
Why?
|
| Male | 42 | 2022 | 364719 | 0.150 |
Why?
|
| Myoglobin | 1 | 2018 | 158 | 0.150 |
Why?
|
| Sheep | 8 | 2010 | 1451 | 0.150 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2008 | 2195 | 0.150 |
Why?
|
| Interleukin-1alpha | 1 | 2018 | 88 | 0.140 |
Why?
|
| Collagen | 7 | 2006 | 2643 | 0.140 |
Why?
|
| Tissue Kallikreins | 1 | 2017 | 14 | 0.140 |
Why?
|
| Enzyme Inhibitors | 8 | 2018 | 3728 | 0.140 |
Why?
|
| Epithelial Cells | 2 | 2007 | 3703 | 0.140 |
Why?
|
| Hydrazones | 1 | 2018 | 105 | 0.140 |
Why?
|
| Interleukin-7 | 1 | 2018 | 146 | 0.140 |
Why?
|
| Mice, SCID | 2 | 2014 | 2627 | 0.140 |
Why?
|
| Oncogene Proteins | 1 | 2001 | 717 | 0.140 |
Why?
|
| Tumor Cells, Cultured | 9 | 2015 | 6124 | 0.140 |
Why?
|
| DNA Primers | 4 | 2012 | 2828 | 0.140 |
Why?
|
| Lung Neoplasms | 8 | 2019 | 13586 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2022 | 5703 | 0.140 |
Why?
|
| beta 2-Microglobulin | 1 | 2018 | 330 | 0.140 |
Why?
|
| Lamin Type A | 1 | 2018 | 190 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2015 | 9419 | 0.140 |
Why?
|
| Endosomes | 1 | 2019 | 522 | 0.130 |
Why?
|
| Quinazolines | 2 | 2015 | 1373 | 0.130 |
Why?
|
| Angiogenesis Inducing Agents | 2 | 2005 | 254 | 0.130 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 5 | 2004 | 1730 | 0.130 |
Why?
|
| Cell Line | 5 | 2019 | 15597 | 0.130 |
Why?
|
| Isoenzymes | 2 | 2011 | 1688 | 0.130 |
Why?
|
| Longitudinal Studies | 4 | 2020 | 14783 | 0.130 |
Why?
|
| Ovary | 2 | 2019 | 965 | 0.130 |
Why?
|
| Kinetics | 4 | 2010 | 6329 | 0.130 |
Why?
|
| Matrix Metalloproteinase 3 | 2 | 2011 | 139 | 0.130 |
Why?
|
| Interleukin-13 | 1 | 2018 | 390 | 0.130 |
Why?
|
| Capillaries | 5 | 2006 | 755 | 0.130 |
Why?
|
| Aqueous Humor | 1 | 1996 | 152 | 0.130 |
Why?
|
| Proteinuria | 1 | 2018 | 611 | 0.130 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2018 | 354 | 0.120 |
Why?
|
| Chickens | 2 | 2015 | 845 | 0.120 |
Why?
|
| Virus Internalization | 1 | 2019 | 504 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2015 | 547 | 0.120 |
Why?
|
| Microcirculation | 4 | 2010 | 1281 | 0.120 |
Why?
|
| Gelatinases | 5 | 2000 | 93 | 0.120 |
Why?
|
| Semaphorins | 1 | 2015 | 96 | 0.120 |
Why?
|
| Protein Transport | 2 | 2019 | 1951 | 0.120 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2017 | 325 | 0.120 |
Why?
|
| Hypertension, Pulmonary | 1 | 2005 | 1605 | 0.120 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2008 | 4352 | 0.120 |
Why?
|
| Troponin I | 1 | 1999 | 662 | 0.120 |
Why?
|
| Fibroblasts | 5 | 2011 | 4176 | 0.120 |
Why?
|
| Immunohistochemistry | 8 | 2012 | 11095 | 0.110 |
Why?
|
| Dioxanes | 2 | 2005 | 36 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 10 | 2022 | 22379 | 0.110 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2012 | 627 | 0.110 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2012 | 856 | 0.110 |
Why?
|
| Gene Expression | 6 | 2012 | 7598 | 0.110 |
Why?
|
| Cholesterol, Dietary | 1 | 2014 | 224 | 0.110 |
Why?
|
| Athletes | 1 | 2021 | 1162 | 0.110 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2008 | 2442 | 0.110 |
Why?
|
| Cell Physiological Phenomena | 1 | 1995 | 152 | 0.110 |
Why?
|
| Cell Adhesion | 5 | 2005 | 3096 | 0.110 |
Why?
|
| Cardiovascular System | 1 | 2001 | 841 | 0.110 |
Why?
|
| Biocompatible Materials | 3 | 2005 | 1702 | 0.110 |
Why?
|
| Cisplatin | 1 | 2019 | 1660 | 0.110 |
Why?
|
| Growth Inhibitors | 2 | 1994 | 375 | 0.110 |
Why?
|
| Materials Testing | 3 | 2006 | 872 | 0.110 |
Why?
|
| Disease Models, Animal | 7 | 2019 | 18349 | 0.110 |
Why?
|
| Neuroglia | 1 | 2019 | 960 | 0.110 |
Why?
|
| Cluster Analysis | 1 | 2020 | 2732 | 0.110 |
Why?
|
| Azetidines | 1 | 2014 | 152 | 0.100 |
Why?
|
| Lysophospholipids | 1 | 2015 | 338 | 0.100 |
Why?
|
| Child | 12 | 2022 | 80917 | 0.100 |
Why?
|
| Umbilical Veins | 2 | 2010 | 424 | 0.100 |
Why?
|
| Stem Cells | 3 | 2015 | 3537 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2015 | 10760 | 0.100 |
Why?
|
| Kidney | 5 | 2022 | 7064 | 0.100 |
Why?
|
| Mice, Inbred BALB C | 2 | 2018 | 6231 | 0.100 |
Why?
|
| Neoplasm Staging | 3 | 2015 | 11244 | 0.100 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 1703 | 0.100 |
Why?
|
| Apoptosis | 5 | 2014 | 9523 | 0.100 |
Why?
|
| Disease Progression | 8 | 2019 | 13671 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 3 | 2017 | 9263 | 0.090 |
Why?
|
| Phenanthrolines | 2 | 2004 | 49 | 0.090 |
Why?
|
| Tretinoin | 1 | 1994 | 524 | 0.090 |
Why?
|
| Vitamin A | 1 | 1994 | 611 | 0.090 |
Why?
|
| Gene Knockout Techniques | 1 | 2014 | 806 | 0.090 |
Why?
|
| Urinary Bladder | 1 | 1997 | 1157 | 0.090 |
Why?
|
| Cell-Derived Microparticles | 1 | 2012 | 160 | 0.090 |
Why?
|
| Enzyme Assays | 1 | 2011 | 103 | 0.090 |
Why?
|
| Open Reading Frames | 3 | 2001 | 818 | 0.090 |
Why?
|
| Adult | 17 | 2021 | 223646 | 0.090 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 5 | 2011 | 1656 | 0.090 |
Why?
|
| Protein Structure, Tertiary | 2 | 2010 | 3772 | 0.090 |
Why?
|
| Child, Preschool | 7 | 2022 | 42669 | 0.090 |
Why?
|
| Fetal Diseases | 2 | 2010 | 916 | 0.090 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 2010 | 64 | 0.090 |
Why?
|
| Fibrosarcoma | 2 | 2003 | 313 | 0.090 |
Why?
|
| Transcription Factors | 4 | 2009 | 12168 | 0.090 |
Why?
|
| Substrate Specificity | 3 | 2007 | 1751 | 0.090 |
Why?
|
| Chick Embryo | 6 | 2003 | 975 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 2 | 2021 | 7477 | 0.080 |
Why?
|
| Pregnancy, Animal | 1 | 2010 | 124 | 0.080 |
Why?
|
| Genetic Vectors | 1 | 2019 | 3402 | 0.080 |
Why?
|
| Blood Platelets | 1 | 2020 | 2479 | 0.080 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2011 | 308 | 0.080 |
Why?
|
| Recombinant Proteins | 4 | 2015 | 6514 | 0.080 |
Why?
|
| Protein Binding | 2 | 2012 | 9343 | 0.080 |
Why?
|
| Collagen Type IV | 2 | 2012 | 125 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2010 | 379 | 0.080 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2011 | 414 | 0.080 |
Why?
|
| Venules | 1 | 2009 | 161 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2003 | 637 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 2 | 2012 | 5797 | 0.080 |
Why?
|
| Neoplasms, Experimental | 4 | 2002 | 1230 | 0.080 |
Why?
|
| Glaucoma | 1 | 2018 | 1194 | 0.080 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2009 | 185 | 0.080 |
Why?
|
| Cell Count | 3 | 2007 | 1832 | 0.080 |
Why?
|
| Protein Biosynthesis | 1 | 1996 | 2094 | 0.080 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2010 | 662 | 0.080 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2012 | 681 | 0.080 |
Why?
|
| Medical Oncology | 1 | 2020 | 2346 | 0.080 |
Why?
|
| Enzyme Activation | 5 | 2005 | 3590 | 0.080 |
Why?
|
| Cathepsins | 1 | 2009 | 243 | 0.080 |
Why?
|
| Carrier Proteins | 1 | 2001 | 4937 | 0.070 |
Why?
|
| Tibia | 1 | 2014 | 1076 | 0.070 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2018 | 2420 | 0.070 |
Why?
|
| Sequence Homology, Amino Acid | 4 | 2003 | 2748 | 0.070 |
Why?
|
| Cell Lineage | 1 | 2017 | 2575 | 0.070 |
Why?
|
| Liver | 2 | 2018 | 7577 | 0.070 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2015 | 1247 | 0.070 |
Why?
|
| Neurosurgical Procedures | 1 | 2018 | 2076 | 0.070 |
Why?
|
| Young Adult | 7 | 2021 | 60066 | 0.070 |
Why?
|
| Prospective Studies | 4 | 2022 | 54926 | 0.070 |
Why?
|
| Cross-Linking Reagents | 1 | 2010 | 693 | 0.070 |
Why?
|
| Densitometry | 2 | 2004 | 151 | 0.070 |
Why?
|
| Aged | 12 | 2017 | 171504 | 0.070 |
Why?
|
| Area Under Curve | 1 | 2011 | 1643 | 0.070 |
Why?
|
| Neoplastic Stem Cells | 1 | 2015 | 1351 | 0.070 |
Why?
|
| Reference Values | 2 | 2009 | 4938 | 0.070 |
Why?
|
| Dimerization | 1 | 2008 | 887 | 0.070 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2015 | 928 | 0.070 |
Why?
|
| Adolescent | 8 | 2018 | 89169 | 0.070 |
Why?
|
| Melanocytes | 2 | 2017 | 509 | 0.070 |
Why?
|
| Nuclear Proteins | 1 | 2001 | 5804 | 0.070 |
Why?
|
| Middle Aged | 13 | 2018 | 223492 | 0.070 |
Why?
|
| Transcriptional Activation | 1 | 2012 | 1750 | 0.070 |
Why?
|
| Pericardium | 1 | 2011 | 679 | 0.070 |
Why?
|
| Tamoxifen | 1 | 2011 | 966 | 0.070 |
Why?
|
| Plastics | 1 | 2007 | 119 | 0.070 |
Why?
|
| Disintegrins | 1 | 2006 | 27 | 0.070 |
Why?
|
| Immunoprecipitation | 1 | 2008 | 874 | 0.070 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2007 | 424 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2011 | 1245 | 0.060 |
Why?
|
| Peptides | 2 | 2004 | 4354 | 0.060 |
Why?
|
| C-Reactive Protein | 1 | 2018 | 3858 | 0.060 |
Why?
|
| Hemangioma | 2 | 2015 | 727 | 0.060 |
Why?
|
| Biodegradation, Environmental | 2 | 2003 | 220 | 0.060 |
Why?
|
| Bone Marrow | 2 | 2020 | 2935 | 0.060 |
Why?
|
| Mesoderm | 1 | 2009 | 679 | 0.060 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2007 | 944 | 0.060 |
Why?
|
| Chorion | 3 | 2003 | 113 | 0.060 |
Why?
|
| Phenotype | 7 | 2010 | 16726 | 0.060 |
Why?
|
| Keratins | 1 | 2007 | 499 | 0.060 |
Why?
|
| Logistic Models | 2 | 2011 | 13290 | 0.060 |
Why?
|
| Chromatography, Affinity | 2 | 2004 | 525 | 0.060 |
Why?
|
| Myeloid Cells | 1 | 2010 | 839 | 0.060 |
Why?
|
| Prolactin | 1 | 2007 | 627 | 0.060 |
Why?
|
| Cholesterol | 1 | 2014 | 2914 | 0.060 |
Why?
|
| Epidermal Growth Factor | 2 | 1998 | 697 | 0.060 |
Why?
|
| PPAR alpha | 1 | 2006 | 177 | 0.060 |
Why?
|
| Cardiac Output, Low | 1 | 2005 | 192 | 0.060 |
Why?
|
| Sclerotherapy | 1 | 2006 | 183 | 0.060 |
Why?
|
| Sensitivity and Specificity | 3 | 2008 | 14729 | 0.060 |
Why?
|
| Immunoblotting | 2 | 2005 | 1647 | 0.060 |
Why?
|
| Rare Diseases | 1 | 2010 | 631 | 0.060 |
Why?
|
| Electrophoresis | 1 | 2004 | 226 | 0.060 |
Why?
|
| Surface Properties | 1 | 2007 | 1166 | 0.060 |
Why?
|
| Chromatography, Ion Exchange | 1 | 2004 | 293 | 0.060 |
Why?
|
| Sepharose | 1 | 2004 | 102 | 0.060 |
Why?
|
| Cell Differentiation | 2 | 2009 | 11669 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2020 | 4755 | 0.060 |
Why?
|
| Ligands | 2 | 2009 | 3284 | 0.060 |
Why?
|
| Ultracentrifugation | 1 | 2004 | 182 | 0.060 |
Why?
|
| Cyclohexanes | 1 | 2004 | 151 | 0.060 |
Why?
|
| Caseins | 1 | 2004 | 105 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2001 | 9615 | 0.060 |
Why?
|
| Edetic Acid | 1 | 2004 | 278 | 0.060 |
Why?
|
| Binding Sites | 1 | 2012 | 6020 | 0.060 |
Why?
|
| Sesquiterpenes | 1 | 2004 | 175 | 0.060 |
Why?
|
| Lymphatic Abnormalities | 1 | 2005 | 134 | 0.050 |
Why?
|
| Leg Ulcer | 1 | 2003 | 71 | 0.050 |
Why?
|
| Awards and Prizes | 1 | 2008 | 365 | 0.050 |
Why?
|
| Skin Absorption | 1 | 2003 | 96 | 0.050 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2014 | 3610 | 0.050 |
Why?
|
| Mucous Membrane | 1 | 2007 | 659 | 0.050 |
Why?
|
| Fibronectins | 2 | 2004 | 722 | 0.050 |
Why?
|
| Reperfusion Injury | 1 | 2010 | 1039 | 0.050 |
Why?
|
| Epilepsy | 1 | 2018 | 3327 | 0.050 |
Why?
|
| Lymphangiogenesis | 1 | 2004 | 171 | 0.050 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2003 | 158 | 0.050 |
Why?
|
| Chelating Agents | 1 | 2004 | 385 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 2 | 2005 | 4786 | 0.050 |
Why?
|
| Catalysis | 1 | 2004 | 768 | 0.050 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2004 | 505 | 0.050 |
Why?
|
| Receptors, Estrogen | 1 | 2011 | 2253 | 0.050 |
Why?
|
| Elastin | 2 | 2001 | 299 | 0.050 |
Why?
|
| Endometrial Neoplasms | 1 | 2012 | 1382 | 0.050 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2006 | 325 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2011 | 1536 | 0.050 |
Why?
|
| COS Cells | 1 | 2004 | 1135 | 0.050 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2003 | 464 | 0.050 |
Why?
|
| Databases as Topic | 1 | 2004 | 472 | 0.050 |
Why?
|
| Carcinoma in Situ | 1 | 2008 | 788 | 0.050 |
Why?
|
| Gene Silencing | 1 | 2009 | 1505 | 0.050 |
Why?
|
| MAP Kinase Signaling System | 2 | 2015 | 1494 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 1 | 2015 | 4413 | 0.050 |
Why?
|
| Myocardium | 2 | 2011 | 4788 | 0.050 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2010 | 2810 | 0.050 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2008 | 1197 | 0.050 |
Why?
|
| Myocytes, Cardiac | 1 | 2011 | 1681 | 0.050 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2007 | 845 | 0.050 |
Why?
|
| Chorioallantoic Membrane | 2 | 2015 | 50 | 0.050 |
Why?
|
| Calciphylaxis | 1 | 2003 | 129 | 0.050 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 3436 | 0.050 |
Why?
|
| Fractures, Bone | 1 | 2014 | 2062 | 0.050 |
Why?
|
| NADH, NADPH Oxidoreductases | 1 | 2002 | 96 | 0.050 |
Why?
|
| History, 21st Century | 1 | 2008 | 1573 | 0.050 |
Why?
|
| Predictive Value of Tests | 3 | 2008 | 15454 | 0.050 |
Why?
|
| Dietary Carbohydrates | 1 | 2006 | 896 | 0.050 |
Why?
|
| Hydroxyproline | 1 | 2001 | 110 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2012 | 12077 | 0.050 |
Why?
|
| Administration, Cutaneous | 1 | 2003 | 716 | 0.050 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2007 | 1966 | 0.050 |
Why?
|
| Actins | 2 | 2007 | 2064 | 0.050 |
Why?
|
| Time Factors | 7 | 2015 | 40218 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2015 | 13014 | 0.050 |
Why?
|
| 3T3 Cells | 2 | 2002 | 1084 | 0.050 |
Why?
|
| Gene Expression Profiling | 3 | 2009 | 9538 | 0.050 |
Why?
|
| Precancerous Conditions | 1 | 2008 | 985 | 0.050 |
Why?
|
| Enzyme Stability | 1 | 2001 | 219 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 3 | 2009 | 6082 | 0.050 |
Why?
|
| Heart Valve Prosthesis | 1 | 2010 | 1468 | 0.050 |
Why?
|
| Kidney Pelvis | 1 | 2022 | 191 | 0.050 |
Why?
|
| Zebrafish | 1 | 2012 | 3035 | 0.050 |
Why?
|
| Collagen Type I | 1 | 2004 | 618 | 0.050 |
Why?
|
| Lymphatic Metastasis | 1 | 2009 | 2914 | 0.050 |
Why?
|
| Proteoglycans | 2 | 2001 | 809 | 0.050 |
Why?
|
| Iron | 1 | 2009 | 1813 | 0.040 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2003 | 311 | 0.040 |
Why?
|
| Precipitin Tests | 1 | 2001 | 816 | 0.040 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2001 | 193 | 0.040 |
Why?
|
| Gene Library | 1 | 2003 | 1064 | 0.040 |
Why?
|
| Heparin | 2 | 1998 | 1636 | 0.040 |
Why?
|
| RNA, Neoplasm | 1 | 2003 | 749 | 0.040 |
Why?
|
| Microspheres | 1 | 2003 | 788 | 0.040 |
Why?
|
| Protective Agents | 1 | 2001 | 150 | 0.040 |
Why?
|
| Zinc | 1 | 2004 | 677 | 0.040 |
Why?
|
| Hydrogels | 1 | 2006 | 744 | 0.040 |
Why?
|
| Cranial Nerve Injuries | 1 | 2000 | 28 | 0.040 |
Why?
|
| Infant | 5 | 2018 | 36535 | 0.040 |
Why?
|
| Culture Techniques | 1 | 2000 | 530 | 0.040 |
Why?
|
| Lingual Nerve | 1 | 2000 | 31 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2006 | 964 | 0.040 |
Why?
|
| Cell Survival | 2 | 2012 | 5777 | 0.040 |
Why?
|
| Taste Disorders | 1 | 2000 | 37 | 0.040 |
Why?
|
| Fatty Liver | 1 | 2006 | 809 | 0.040 |
Why?
|
| United States | 3 | 2021 | 73039 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2008 | 2766 | 0.040 |
Why?
|
| Polyglactin 910 | 1 | 1999 | 56 | 0.040 |
Why?
|
| Pancreatic Elastase | 1 | 1999 | 125 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2004 | 1826 | 0.040 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2004 | 541 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2008 | 6229 | 0.040 |
Why?
|
| Bucladesine | 1 | 1999 | 118 | 0.040 |
Why?
|
| Urethral Obstruction | 1 | 1999 | 56 | 0.040 |
Why?
|
| 5' Untranslated Regions | 1 | 2001 | 255 | 0.040 |
Why?
|
| Thiazolidinediones | 1 | 2002 | 461 | 0.040 |
Why?
|
| Plasmids | 1 | 2004 | 2269 | 0.040 |
Why?
|
| Kidney Diseases | 1 | 2010 | 2100 | 0.040 |
Why?
|
| Hemangioendothelioma | 1 | 1999 | 112 | 0.040 |
Why?
|
| Fibrosis | 3 | 2010 | 2080 | 0.040 |
Why?
|
| Homeostasis | 2 | 2011 | 3348 | 0.040 |
Why?
|
| Membranes, Artificial | 1 | 2000 | 367 | 0.040 |
Why?
|
| Sequence Analysis | 1 | 1999 | 240 | 0.040 |
Why?
|
| Africa South of the Sahara | 1 | 2021 | 752 | 0.040 |
Why?
|
| Transplantation, Autologous | 2 | 2000 | 2120 | 0.040 |
Why?
|
| 3' Untranslated Regions | 1 | 2001 | 515 | 0.040 |
Why?
|
| Taste | 1 | 2000 | 190 | 0.040 |
Why?
|
| Sex Factors | 2 | 2018 | 10632 | 0.040 |
Why?
|
| Hemangiosarcoma | 1 | 2000 | 215 | 0.040 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 1998 | 124 | 0.040 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2002 | 859 | 0.040 |
Why?
|
| Rabbits | 3 | 2012 | 4772 | 0.040 |
Why?
|
| Cornea | 3 | 2004 | 1316 | 0.040 |
Why?
|
| Chromosome Mapping | 1 | 2006 | 4620 | 0.040 |
Why?
|
| Transfection | 1 | 2005 | 5755 | 0.040 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2000 | 462 | 0.040 |
Why?
|
| Protein Engineering | 1 | 2001 | 553 | 0.040 |
Why?
|
| Urinary Bladder Neck Obstruction | 1 | 1997 | 82 | 0.030 |
Why?
|
| Endostatins | 2 | 2012 | 167 | 0.030 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 1997 | 69 | 0.030 |
Why?
|
| Aorta, Abdominal | 1 | 1999 | 627 | 0.030 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 1999 | 481 | 0.030 |
Why?
|
| Disease-Free Survival | 3 | 2017 | 6847 | 0.030 |
Why?
|
| Adrenal Cortex | 2 | 2003 | 134 | 0.030 |
Why?
|
| Estrus | 1 | 1996 | 70 | 0.030 |
Why?
|
| Stroke | 1 | 2018 | 9755 | 0.030 |
Why?
|
| Fetus | 2 | 2010 | 1883 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2017 | 59629 | 0.030 |
Why?
|
| Extracellular Space | 1 | 1998 | 563 | 0.030 |
Why?
|
| Colitis, Ulcerative | 1 | 2008 | 1926 | 0.030 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 1997 | 256 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2003 | 2846 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2001 | 1715 | 0.030 |
Why?
|
| Megakaryocytes | 1 | 2020 | 571 | 0.030 |
Why?
|
| Leukemia Virus, Murine | 1 | 2016 | 95 | 0.030 |
Why?
|
| Crohn Disease | 1 | 2008 | 2295 | 0.030 |
Why?
|
| Receptors, Cannabinoid | 1 | 2015 | 43 | 0.030 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2000 | 956 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2009 | 8741 | 0.030 |
Why?
|
| Neoplasms, Vascular Tissue | 1 | 2015 | 25 | 0.030 |
Why?
|
| Pharmaceutical Preparations | 1 | 2003 | 1088 | 0.030 |
Why?
|
| Carotid Arteries | 1 | 1999 | 942 | 0.030 |
Why?
|
| Sarcoma 180 | 1 | 1994 | 6 | 0.030 |
Why?
|
| Thiazoles | 1 | 2002 | 1542 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 39348 | 0.030 |
Why?
|
| Biological Availability | 1 | 2015 | 389 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2003 | 2393 | 0.030 |
Why?
|
| Polysaccharide-Lyases | 1 | 1994 | 48 | 0.030 |
Why?
|
| Coronary Vessels | 1 | 2005 | 3124 | 0.030 |
Why?
|
| Sarcoma, Experimental | 1 | 1994 | 117 | 0.030 |
Why?
|
| Women's Health | 1 | 2004 | 2082 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2002 | 2149 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 1998 | 2179 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 1998 | 1207 | 0.030 |
Why?
|
| Brain Stem | 1 | 2018 | 859 | 0.030 |
Why?
|
| Mutation | 1 | 2018 | 30238 | 0.030 |
Why?
|
| Wounds and Injuries | 1 | 2006 | 2517 | 0.030 |
Why?
|
| Fibrinolytic Agents | 1 | 2003 | 2080 | 0.030 |
Why?
|
| Ferric Compounds | 1 | 2014 | 376 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2015 | 615 | 0.030 |
Why?
|
| Conserved Sequence | 1 | 1996 | 1162 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2001 | 2885 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2003 | 2954 | 0.030 |
Why?
|
| Genomics | 1 | 2008 | 5926 | 0.030 |
Why?
|
| Aging | 1 | 2011 | 8744 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2015 | 693 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 1793 | 0.020 |
Why?
|
| Pulmonary Artery | 1 | 2000 | 1946 | 0.020 |
Why?
|
| Heart Rate | 1 | 2003 | 4214 | 0.020 |
Why?
|
| Age of Onset | 1 | 2018 | 3347 | 0.020 |
Why?
|
| Creatinine | 2 | 2010 | 1918 | 0.020 |
Why?
|
| Severity of Illness Index | 3 | 2018 | 15948 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2017 | 1196 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 937 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 2003 | 2541 | 0.020 |
Why?
|
| Oncogenes | 1 | 1997 | 1234 | 0.020 |
Why?
|
| Organ Specificity | 1 | 1996 | 1968 | 0.020 |
Why?
|
| Hydrocortisone | 1 | 1999 | 1841 | 0.020 |
Why?
|
| Scapula | 1 | 1992 | 175 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2013 | 24315 | 0.020 |
Why?
|
| Caveolin 1 | 1 | 2012 | 255 | 0.020 |
Why?
|
| Swine | 2 | 2003 | 5995 | 0.020 |
Why?
|
| Chronic Disease | 2 | 2021 | 9384 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2010 | 2062 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1991 | 1057 | 0.020 |
Why?
|
| Matrix Metalloproteinases, Secreted | 1 | 2010 | 13 | 0.020 |
Why?
|
| Incidence | 1 | 2008 | 21538 | 0.020 |
Why?
|
| Cystatin A | 1 | 2009 | 6 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2014 | 1760 | 0.020 |
Why?
|
| Cystatin B | 1 | 2009 | 13 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 1999 | 2167 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2014 | 2474 | 0.020 |
Why?
|
| Heart Injuries | 1 | 2011 | 207 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2014 | 2486 | 0.020 |
Why?
|
| Pressure | 1 | 2012 | 1172 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2015 | 2357 | 0.020 |
Why?
|
| Neutrophils | 1 | 2001 | 3786 | 0.020 |
Why?
|
| Age Factors | 1 | 2005 | 18412 | 0.020 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1995 | 1493 | 0.020 |
Why?
|
| In Situ Hybridization | 2 | 2003 | 1903 | 0.020 |
Why?
|
| Autoantigens | 1 | 2012 | 890 | 0.020 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2009 | 199 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 1 | 1 | 2007 | 11 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2008 | 26422 | 0.020 |
Why?
|
| Models, Biological | 3 | 2012 | 9495 | 0.020 |
Why?
|
| Hot Temperature | 1 | 1994 | 1441 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2015 | 4030 | 0.020 |
Why?
|
| Biological Assay | 1 | 1990 | 628 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 1991 | 969 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 1992 | 2678 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 2010 | 921 | 0.020 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2008 | 268 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2008 | 526 | 0.020 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2005 | 59 | 0.020 |
Why?
|
| Peptide Library | 1 | 2007 | 351 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2008 | 348 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2007 | 474 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2007 | 478 | 0.020 |
Why?
|
| Luciferases | 1 | 2007 | 713 | 0.020 |
Why?
|
| Growth Hormone | 1 | 2007 | 573 | 0.010 |
Why?
|
| Calcium | 1 | 1998 | 5792 | 0.010 |
Why?
|
| Ventricular Pressure | 1 | 2005 | 210 | 0.010 |
Why?
|
| Polystyrenes | 1 | 2005 | 105 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor D | 1 | 2004 | 61 | 0.010 |
Why?
|
| Fibroblast Growth Factors | 1 | 1990 | 873 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2004 | 125 | 0.010 |
Why?
|
| Dipeptides | 1 | 2005 | 386 | 0.010 |
Why?
|
| Transducers | 1 | 2004 | 243 | 0.010 |
Why?
|
| Neuropeptides | 1 | 2009 | 951 | 0.010 |
Why?
|
| Periodicity | 1 | 2004 | 348 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2007 | 1524 | 0.010 |
Why?
|
| Physical Stimulation | 1 | 2004 | 517 | 0.010 |
Why?
|
| Injections | 1 | 2006 | 840 | 0.010 |
Why?
|
| Prenatal Diagnosis | 1 | 2010 | 1275 | 0.010 |
Why?
|
| Melanoma | 2 | 2017 | 5706 | 0.010 |
Why?
|
| Multiprotein Complexes | 1 | 2009 | 1110 | 0.010 |
Why?
|
| Organ Size | 1 | 2008 | 2267 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2007 | 1743 | 0.010 |
Why?
|
| Elasticity | 1 | 2004 | 656 | 0.010 |
Why?
|
| Corneal Neovascularization | 1 | 2004 | 184 | 0.010 |
Why?
|
| Homozygote | 1 | 2007 | 1779 | 0.010 |
Why?
|
| Protein Kinases | 1 | 2009 | 1611 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2003 | 287 | 0.010 |
Why?
|
| Sirolimus | 1 | 2009 | 1540 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 8542 | 0.010 |
Why?
|
| Prostate | 1 | 2010 | 1765 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 2004 | 1765 | 0.010 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2010 | 1772 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 6526 | 0.010 |
Why?
|
| Biomedical Research | 1 | 2017 | 3463 | 0.010 |
Why?
|
| Embryo, Mammalian | 1 | 2007 | 1676 | 0.010 |
Why?
|
| Transcription Factor AP-1 | 1 | 2003 | 321 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 1998 | 4282 | 0.010 |
Why?
|
| Research Design | 1 | 2017 | 6211 | 0.010 |
Why?
|
| Agar | 1 | 2000 | 51 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2011 | 3447 | 0.010 |
Why?
|
| Receptors, Growth Factor | 1 | 2002 | 324 | 0.010 |
Why?
|
| Chromones | 1 | 2000 | 148 | 0.010 |
Why?
|
| Echocardiography | 2 | 2005 | 5047 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2002 | 1550 | 0.010 |
Why?
|
| Enzyme Precursors | 1 | 2000 | 166 | 0.010 |
Why?
|
| Inflammation | 1 | 2020 | 10873 | 0.010 |
Why?
|
| Collagen Type XVIII | 1 | 1999 | 52 | 0.010 |
Why?
|
| Larynx | 1 | 2005 | 492 | 0.010 |
Why?
|
| Porosity | 1 | 2000 | 352 | 0.010 |
Why?
|
| Stress, Mechanical | 1 | 2004 | 1676 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 6669 | 0.010 |
Why?
|
| Trachea | 1 | 2005 | 1095 | 0.010 |
Why?
|
| Cell Size | 1 | 2000 | 626 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2002 | 560 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2002 | 2300 | 0.010 |
Why?
|
| Ventricular Remodeling | 1 | 2005 | 1281 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 2000 | 855 | 0.010 |
Why?
|
| Pregnancy | 2 | 2010 | 30256 | 0.010 |
Why?
|
| Pulmonary Circulation | 1 | 2000 | 745 | 0.010 |
Why?
|
| Heart | 1 | 2011 | 4446 | 0.010 |
Why?
|
| Glycosaminoglycans | 1 | 2000 | 611 | 0.010 |
Why?
|
| Biotechnology | 1 | 1999 | 283 | 0.010 |
Why?
|
| Cell Transplantation | 1 | 1999 | 475 | 0.010 |
Why?
|
| Skin | 1 | 2011 | 4503 | 0.010 |
Why?
|
| Morpholines | 1 | 2000 | 584 | 0.010 |
Why?
|
| Flavonoids | 1 | 2000 | 447 | 0.010 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1993 | 3781 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2015 | 36743 | 0.010 |
Why?
|
| Lung | 1 | 1996 | 10099 | 0.010 |
Why?
|
| Connective Tissue | 1 | 1999 | 425 | 0.010 |
Why?
|
| Body Weight | 1 | 2008 | 4627 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1998 | 826 | 0.010 |
Why?
|
| H-2 Antigens | 1 | 1997 | 359 | 0.010 |
Why?
|
| Simian virus 40 | 1 | 1997 | 292 | 0.010 |
Why?
|
| Veins | 1 | 2000 | 769 | 0.010 |
Why?
|
| Vascular Patency | 1 | 1999 | 917 | 0.010 |
Why?
|
| Graft Occlusion, Vascular | 1 | 1999 | 538 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2007 | 8317 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1997 | 866 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1996 | 863 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 1999 | 931 | 0.010 |
Why?
|
| Androstadienes | 1 | 1997 | 348 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 1998 | 863 | 0.010 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 1997 | 434 | 0.010 |
Why?
|
| Heparin Lyase | 1 | 1994 | 37 | 0.010 |
Why?
|
| Cell Hypoxia | 1 | 1997 | 662 | 0.010 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2002 | 1627 | 0.010 |
Why?
|
| Microsurgery | 1 | 2000 | 800 | 0.010 |
Why?
|
| Biopsy | 1 | 2006 | 6793 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2001 | 1502 | 0.010 |
Why?
|
| Protein Precursors | 1 | 1998 | 1134 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 1994 | 636 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2009 | 14488 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2000 | 2932 | 0.010 |
Why?
|
| Histones | 1 | 2003 | 2601 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2011 | 65371 | 0.010 |
Why?
|
| Weight Loss | 1 | 2003 | 2721 | 0.010 |
Why?
|
| Progesterone | 1 | 1996 | 752 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1994 | 1534 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2011 | 11519 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1998 | 3740 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1997 | 3655 | 0.000 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 1997 | 2885 | 0.000 |
Why?
|
| DNA | 1 | 1999 | 7214 | 0.000 |
Why?
|
| Retrospective Studies | 1 | 2000 | 81762 | 0.000 |
Why?
|